LUCID MOOD

Brand Owner (click to sort) Address Description
LUCIDMOOD Chooze, Corp. 4730 Table Mesa Drive A100 Boulder CO 80305 LUCID MOOD;Electric cigarettes; Electric vaporizers, namely, oral vaporizers for smokers; Smokeless cigarette vaporizer pipes; Smokeless cigar vaporizer pipes; Cartridges sold filled with chemical flavorings in liquid form for electric cigarettes; Electric cigarette liquid (e-liquid) comprised of vegetable glycerin; Combustible plant material; Flavoring additives for use with electronic cigarettes; Chemical flavorings in liquid form used to refill electric cigarette cartridges; Electric cigarette refill cartridges sold empty; Cigarette lighters not for land vehicles;
LUCIDMOOD Chooze, Corp. 4730 Table Mesa Drive A100 Boulder CO 80305 LUCID MOOD;Terpenes being essential oils for flavoring beverages; Body care products, namely, shampoo, conditioners, and body wash; Terpenes being essential oils for personal use; Terpenes being essential oils for use in aromatherapy;
LUCIDMOOD PALMER JANE, INC. 102 E. 1ST STREET SUITE 200 LOVELAND CO 80537 LUCID MOOD;Electric cigarettes; electronic smoking pipes; smokeless vaporizer pens; electronic oral vaporizers for smoking purposes; all of the foregoing sold empty;
LUCIDMOOD PALMER JANE, INC. 102 E. 1ST STREET SUITE 200 LOVELAND CO 80537 LUCID MOOD;Providing health and wellness information; providing health and wellness information about the effects of terpenes and cannabinoids; providing a website featuring information about health and wellness; providing a website featuring health and wellness information about the effects of terpenes and cannabinoids;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas.